What does this research mean for the field?

Adults with type 1 diabetes who experience at least one hypoglycemia event have higher rates of diabetes-related complications and 14% higher annual direct healthcare costs compared to the broader type 1 diabetes population. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the clinical burden of diabetes-related complications and annual direct healthcare costs among adults with type 1 diabetes with and without documented hypoglycemia in the United States.

September 14, 2026Journal of Medical EconomicsOpen Access

Retrospective database analysis of annual direct costs and complications for patients with type 1 diabetes and hypoglycemia in the US

View Full Paper

Ask AI

Bookmark

Authors

ABAdriana Boateng-Kuffour NLNanxin Li VAVamshi Ruthwik Anupindi

Discussion

Member takes

Overview

Retrospective cohort study finds higher complication rates and 14% greater annual costs in adults with type 1 diabetes and hypoglycemia, highlighting heightened clinical complexity.

Key Points

To assess the clinical burden of diabetes-related complications and annual direct healthcare costs among adults with type 1 diabetes with and without documented hypoglycemia in the United States.
Conducted a retrospective cohort study using IQVIA's PharMetrics Plus database evaluating adults (≥18 years) with type 1 diabetes diagnoses between April 1, 2016, and April 30, 2020, followed through April 30, 2022.
Compared outcomes between all individuals with type 1 diabetes (cohort 1, N=96,946) and a subgroup with at least one documented hypoglycemia claim (cohort 2, N=18,556).
Descriptively summarized prevalence rates of microvascular and macrovascular complications and quantified total all-cause direct medical costs per patient per year (PPPY).
Of 96,946 adults with type 1 diabetes, 18,556 (19.1%) had at least one hypoglycemia claim during the study period.
Complication rates were consistently higher in the hypoglycemia cohort than the overall cohort, including retinopathy (34.0% vs. 26.9%), neuropathy (30.2% vs. 21.7%), nephropathy (7.4% vs. 4.7%), chronic kidney disease (9.3% vs. 6.6%), coronary artery disease (7.6% vs. 5.8%), and peripheral vascular disease (7.6% vs. 5.2%).
Total all-cause direct costs PPPY were 14% higher for patients with hypoglycemia claims ($29,903 in 2022 USD; $33,790 in 2025 USD) compared with the broader type 1 diabetes population ($26,293 in 2022 USD; $29,711 in 2025 USD).

Cite This Study

Boateng-Kuffour et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3950926e14a848b2aa1 https://doi.org/10.1080/13696998.2026.2729739

View Full Paper

Ask AI

Bookmark

September 14, 2026Journal of Medical EconomicsOpen Access

Retrospective database analysis of annual direct costs and complications for patients with type 1 diabetes and hypoglycemia in the US

View Full Paper

Ask AI

Bookmark

Authors

ABAdriana Boateng-Kuffour NLNanxin Li VAVamshi Ruthwik Anupindi

Discussion

Member takes

Overview

Retrospective cohort study finds higher complication rates and 14% greater annual costs in adults with type 1 diabetes and hypoglycemia, highlighting heightened clinical complexity.

Key Points

To assess the clinical burden of diabetes-related complications and annual direct healthcare costs among adults with type 1 diabetes with and without documented hypoglycemia in the United States.
Conducted a retrospective cohort study using IQVIA's PharMetrics Plus database evaluating adults (≥18 years) with type 1 diabetes diagnoses between April 1, 2016, and April 30, 2020, followed through April 30, 2022.
Compared outcomes between all individuals with type 1 diabetes (cohort 1, N=96,946) and a subgroup with at least one documented hypoglycemia claim (cohort 2, N=18,556).
Descriptively summarized prevalence rates of microvascular and macrovascular complications and quantified total all-cause direct medical costs per patient per year (PPPY).
Of 96,946 adults with type 1 diabetes, 18,556 (19.1%) had at least one hypoglycemia claim during the study period.
Complication rates were consistently higher in the hypoglycemia cohort than the overall cohort, including retinopathy (34.0% vs. 26.9%), neuropathy (30.2% vs. 21.7%), nephropathy (7.4% vs. 4.7%), chronic kidney disease (9.3% vs. 6.6%), coronary artery disease (7.6% vs. 5.8%), and peripheral vascular disease (7.6% vs. 5.2%).
Total all-cause direct costs PPPY were 14% higher for patients with hypoglycemia claims ($29,903 in 2022 USD; $33,790 in 2025 USD) compared with the broader type 1 diabetes population ($26,293 in 2022 USD; $29,711 in 2025 USD).

Cite This Study

Boateng-Kuffour et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3950926e14a848b2aa1 https://doi.org/10.1080/13696998.2026.2729739

View Full Paper

Ask AI

Bookmark